Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/20/26 19:59 | 1/20/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Lubner David Charles | CA | D | 2 | M.d | 488 | 40.64 | 0 | 12 | 124 | 22 | D | |||||||||||||||
1/20/26 19:59 | 1/20/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Lubner David Charles | CA | D | 2 | S.d | -488 | 40.64 | 0 | -12 | 22 | D | ||||||||||||||||
1/14/26 19:38 | 1/6/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Heery Christopher | CA | O | CHIEF ME | 8 | M.dm | 1,314 | 12.52 | 0 | 105 | 43 | D | |||||||||||||||
1/14/26 19:38 | 1/14/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Heery Christopher | CA | O | CHIEF ME | 8 | S.dm | -1,314 | 12.52 | 0 | -105 | 43 | D | |||||||||||||||
1/6/26 20:15 | 1/2/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Elghandour Rami | CA | DO | SEE REMA | 1 | M.dm | 0 | 0.00 | 0 | 165 | 27 | 782 | D | ||||||||||||||
1/6/26 20:14 | 1/2/26 | ACLX | Health | BioPrd | Biological Products, (No Diag | Gilson Michelle | CA | O | CFO | 1 | M.dm | 0 | 0.00 | 0 | 56 | 666 | 65 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |